Fig. 2.

MDM2 inhibition reduces tumour growth and proliferation markers in an ER+ breast cancer PDX model. a Growth of the treatment naïve KCC_P_3837 PDX model of ER+ breast cancer treated with vehicle (2% DMSO daily, grey, n = 5) and NVP-CGM097 (100 mg/kg daily, red, n = 4) for 60 days. b Representative images and quantification of the proliferation marker Ki-67 at endpoint. Ki-67 positive proportions from three independent replicates per treatment were compared by two-tailed T test. Bar = 50 μm